Filing Details
- Accession Number:
- 0000899243-19-026595
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-11-04 17:51:26
- Reporting Period:
- 2019-11-04
- Accepted Time:
- 2019-11-04 17:51:26
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1720725 | Oyster Point Pharma Inc. | OYST | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1228684 | Phd J William Link | C/O Oyster Point Pharma, Inc. 202 Carnegie Center, Suite 109 Princeton NJ 08540 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.001 Per Share | Acquisiton | 2019-11-04 | 10,420 | $0.00 | 12,438 | No | 4 | C | Indirect | See footnotes |
Common Stock, Par Value $0.001 Per Share | Acquisiton | 2019-11-04 | 1,654,359 | $0.00 | 1,974,798 | No | 4 | C | Indirect | See footnotes |
Common Stock, Par Value $0.001 Per Share | Acquisiton | 2019-11-04 | 27,500 | $16.00 | 2,002,298 | No | 4 | P | Indirect | See footnotes |
Common Stock, Par Value $0.001 Per Share | Acquisiton | 2019-11-04 | 955,392 | $0.00 | 955,392 | No | 4 | C | Indirect | See footnotes |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See footnotes |
No | 4 | C | Indirect | See footnotes |
No | 4 | P | Indirect | See footnotes |
No | 4 | C | Indirect | See footnotes |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.001 Per Share | Series A Convertible Preferred Stock | Disposition | 2019-11-04 | 10,420 | $0.00 | 10,420 | $0.00 |
Common Stock, Par Value $0.001 Per Share | Series A Convertible Preferred Stock | Disposition | 2019-11-04 | 1,654,359 | $0.00 | 1,654,359 | $0.00 |
Common Stock, Par Value $0.001 Per Share | Series B Convertible Preferred Stock | Disposition | 2019-11-04 | 955,392 | $0.00 | 955,392 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- Shares held by Versant Side Fund IV, L.P. ("Versant Side Fund IV").
- Shares held by Versant Venture Capital IV, L.P. ("Versant IV").
- The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant IV and Versant Side Fund IV. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- Shares held by Oyster Point Pharma I, L.L.C. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Oyster Point Pharma I, L.L.C.